Guggenheim initiated coverage of Precision BioSciences with a Buy rating and $19 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DTIL:
- Precision BioSciences Faces Partnership Termination, Eyes Future
- Precision announces return of programs, conclusion of collab with Prevail
- iECURE announces FDA clearance of IND application for ECUR-506
- Precision BioSciences price target raised to $30 from $2 at BTIG
- Precision Biosciences Battles Delisting Risk: Reverse Split to Rescue Stock Price